Abstract | OBJECTIVES: METHODS: Thirty-five patients with prolactinoma at baseline and twenty-one who completed the 6-month DA treatment were submitted to clinical/laboratorial evaluations, polysomnography and abdominal imaging. RESULTS: Before treatment, the prevalence of obesity/ overweight and OSA were, respectively, 68.5 and 34.2 %. We found a positive correlation between AHI and weight (r = 0.57; p < 0.001), BMI (r = 0.56; p < 0.001), WC (r = 0.61; p < 0.001), VFV (r = 0.55; p = 0.002), insulin levels (r = 0.57; p < 0.001), and HOMA-IR index (r = 0.57; p < 0.001); and a negative correlation between AHI and HDL-cholesterol (r = -0.47; p = 0.005). After multivariate analysis, VFV and insulin levels were the most important predictors for AHI (p = 0.001 and p = 0.02, respectively). After DA, the obesity/ overweight and OSA prevalence did not change. CONCLUSIONS:
|
Authors | Flávia Regina Pinho Barbosa, Cintia Marques dos Santos Silva, Giovanna Aparecida Balarini Lima, Giovanna Aparecida Balarinni Lima, Leila Warszawski, Romeu Cortes Domingues, Michele Dominic, Rosita Fontes, Leonardo Vieira Neto, Mônica Roberto Gadelha |
Journal | Pituitary
(Pituitary)
Vol. 17
Issue 5
Pg. 441-9
(Oct 2014)
ISSN: 1573-7403 [Electronic] United States |
PMID | 24068456
(Publication Type: Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Dopamine Agonists
- Prolactin
|
Topics |
- Adult
- Aged
- Body Mass Index
- Dopamine Agonists
(pharmacology, therapeutic use)
- Female
- Humans
- Hyperprolactinemia
(drug therapy, epidemiology)
- Male
- Middle Aged
- Prolactin
(blood)
- Prolactinoma
(blood, complications, drug therapy, epidemiology)
- Sleep Apnea, Obstructive
(blood, complications, drug therapy, epidemiology)
- Waist Circumference
(drug effects)
- Young Adult
|